Related Experiment Video
Updated: May 12, 2026
04:15
A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Published on: February 2, 2024
Integrin αIIbβ3: from discovery to efficacious therapeutic target
Kamila Bledzka1, Susan S Smyth, Edward F Plow
1Department of Molecular Cardiology, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Circulation Research
|April 13, 2013
Summary
Platelet aggregation, mediated by integrin αIIbβ3, is crucial for preventing bleeding but can cause thrombosis. αIIbβ3 antagonists like abciximab, eptifibatide, and tirofiban have saved lives but have bleeding side effects.
Area of Science:
- Cardiovascular Biology
- Hematology
- Pharmacology
Background:
- Platelets aggregate to prevent bleeding but excessive aggregation causes thrombosis.
- Integrin αIIbβ3 is a key platelet membrane protein mediating aggregation by binding bridging ligands.
- Dysfunctional platelet aggregation causes bleeding disorders (Glanzmann thrombasthenia) or thrombotic diseases.
Purpose of the Study:
- To review the biology of integrin αIIbβ3.
- To discuss the development and clinical application of αIIbβ3 antagonists.
- To examine the successes and limitations of αIIbβ3 antagonism in treating thrombotic diseases.
Main Methods:
- Review of scientific literature on platelet aggregation and αIIbβ3.
- Analysis of preclinical and clinical trial data for αIIbβ3 antagonists.
- Examination of Food and Drug Administration-approved αIIbβ3 antagonists.
Main Results:
- Integrin αIIbβ3 antagonists (abciximab, eptifibatide, tirofiban) were developed and approved.
- Millions of patients treated, saving lives, particularly during percutaneous coronary interventions.
- Increased bleeding risk and newer antithrombotics are leading to decreased use, though still vital for specific procedures.
Conclusions:
- αIIbβ3 antagonists have been pivotal in managing acute coronary syndromes and preventing periprocedural thrombosis.
- Despite waning use due to bleeding risks and newer agents, they remain important in specific interventional cardiology contexts.
- Understanding αIIbβ3 biology and antagonism provides insights into thrombosis and hemostasis management.
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
01:10Integrins
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:31Immunoglobulin-like Cell Adhesion Molecules
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.